Although the immediate market response was negative, most pharmaceutical stocks recovered after Wall Street analysts ...

Pharmaceutical stocks, including Pfizer (NYSE: PFE ... rebounded after Wall Street analysts highlighted the significant legal challenges the order would face. The pharmaceutical industry has ...

BMO Capital cut Terns Pharmaceuticals' price target from $26 to $15, citing costlier capital conditions despite maintaining ...

This investigation has raised concerns about potential legal and reputational ... the approval process for Pfizer’s vaccine candidates. Despite these challenges, Pfizer maintains a Moderate ...

A top European court has ruled that the European Commission was wrong to refuse The New York Times access to text messages ...

Berlaymont has been closely watching the highly anticipated legal ruling on transparency around the European Union’s vaccine deal with pharmaceutical giant Pfizer. Pfizergate is the name of the ...

Shares of U.S. drugmakers rebounded on Monday after an initial selloff as analysts said that President Donald Trump's ...

The European Court of Justice has upheld a transparency challenge over undisclosed text messages between EU Commission ...

Global pharmaceutical shares jumped in intraday trading Monday, reversing their pre-market declines, as investors anticipated ...

The pressure to strategize on its pipeline comes as Pfizer prepares for new challenges. The company is bracing for a more than $15 billion loss over the next decade as patents for six major drugs ...